JIA Juvenile Idiopathic Arthritis
Conditions
Interventions
There is only one study group. All participant patients will be offered a
control interval of 6 months instead of the current 3 months. All patients will
complete a JAMAR and EQ-5D-5L-Y questionnair
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: -JIA diagnosis of >=1 year -age 6 - 20 years -Clinical remission, defined as cJADAS
Exclusion criteria
Exclusion criteria: -use of steroids -not able to read or understand Dutch language -not able or willing to use e-mail
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter will be the number of disease flares observed at the 6-month visit. Disease flares are defined as a JADAS score of higher than 3. | — |
Secondary
| Measure | Time frame |
|---|---|
| - The number of rescheduled visits due to presumed disease worsening as well as the percentage of correctly rescheduled visits (e.g. observation of a flare during the rescheduled visit). - The number of reminders sent for filling out the questionnaires at the 3 month moment and the number of patients that fail to home monitor themselves. Exploratory outcomes: - Description of events of specific interest during home self-monitoring: presumed medication related events (side effects) - Relationship between JAMAR answers using self-evaluation and active joint count and PGA at the scheduled 6-month visit - Validation of EQ-5D and EQ-VAS score cut-offs as indicators of stable disease. - satisfaction with home monitoring using a separate questionnaire | — |
Countries
Netherlands
Outcome results
None listed